Philip M Sass

USPTO Granted Patents = 58 (Patent Applications = 4)

CIPO Patents = 13 (Patent Applications = 2)

EPO Patents = 14 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 267(Granted Patents)

Forward Citations (Not Self Cited) = 178(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Audobon, PA (US) (2009 - 2013)
Audubon, PA (US) (2003 - 2019)

Company Filing History:

The Johns Hopkins University

4. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2019

Loading Chart...

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10509037 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2019-12-17),

2. 10364284 - High affinity antibodies that neutralizeenterotoxin B (2019-07-30),

3. 10253106 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2019-04-09),

4. 10053509 - Methods for inhibiting the binding of endosialin to ligands (2018-08-21),

5. 10023632 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2018-07-17),

6. 9868780 - [object Object] (2018-01-16),

7. 9650440 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-05-16),

8. 9624297 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-04-18),

9. 9522195 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2016-12-20),

10. 9505842 - Methods for inhibiting the binding of endosialin to ligands (2016-11-29),

11. 9422367 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2016-08-23),

12. 9359428 - [object Object] (2016-06-07),

13. 9144614 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2015-09-29),

14. 9115197 - Anti-mesothelin antibodies (2015-08-25),

15. 8956832 - Cells expressing anti-GD2 antibodies and methods related thereto (2015-02-17),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I will provide you with an article on inventor Philip M Sass based on the given data.

Title: The Innovative Mind Behind Cancer Treatment Breakthroughs: Philip M Sass

Introduction:

Philip M Sass, a prolific inventor hailing from Audubon, PA (US), is a distinguished figure in the realm of biomedical research and innovation. With an impressive portfolio of 58 patents under his belt, Sass's contributions have significantly advanced the field of cancer treatment.

Latest Patents:

Sass's latest patents showcase his groundbreaking work in developing monoclonal antibodies that target the alpha-folate receptor, a critical component in the treatment of various cancers. These antibodies have shown promising results in inhibiting the biological activity of folate receptor-α (FR-α) and have potential applications in treating ovarian, breast, renal, colorectal, lung, endometrial, and brain cancers. Additionally, Sass has also patented high-affinity antibodies that neutralize enterotoxin B, offering innovative solutions for diseases mediated by this toxin.

Career Highlights:

Throughout his career, Philip M Sass has made significant contributions to the field of biotechnology. He has notably worked at renowned companies such as Morphotek, Inc., and The Johns Hopkins University, where his innovative research has paved the way for groundbreaking medical advancements in cancer treatment.

Collaborations:

Sass has collaborated with esteemed professionals in the industry, including Luigi Grasso and Nicholas C Nicolaides, whose expertise and teamwork have further enriched his innovative projects. Together, they have fostered a culture of collaboration and excellence in their pursuit of cutting-edge solutions for complex medical challenges.

Conclusion:

In conclusion, Philip M Sass's inventive spirit and dedication to advancing medical science have positioned him as a trailblazer in the field of cancer treatment. His patents reflect a commitment to innovation and a relentless pursuit of improving patient outcomes, making him a respected figure in the world of biomedical research and development.

This text is generated by artificial intelligence and may not be accurate.